Lidocaine sustained release formulation - Sustained Therapeutics
Alternative Names: ST-01- Sustained TherapeuticsLatest Information Update: 14 Apr 2026
At a glance
- Originator Sustained Therapeutics
- Class Acetanilides; Analgesics; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pain; Postoperative pain
Most Recent Events
- 21 Jan 2026 Sustained Therapeutics completes a phase II trials in Pain in Canada (Parenteral) (NCT05707208)
- 08 Jan 2026 Sustained Therapeutics plans to file IND applications with the US FDA and Health Canada for phase-III trial in Pain
- 08 Jan 2026 Interim adverse events and efficacy data from a phase-II trial in Pain released by Sustained Therapeutics